Literature DB >> 10738478

Risk management: how doctors, hospitals and MDOs can limit the costs of malpractice litigation.

L L Wilson1, M Fulton.   

Abstract

The concerns of doctors regarding their risk of malpractice litigation and the costs of indemnity premiums are resulting in calls for legal reforms to limit their liability. We do not believe these returns will be successful either practically or politically. Medical defence organisations often attempt to vindicate the doctor rather than settle the dispute--a strategy that might be morally satisfying to doctors but which is also more expensive than the approach taken by commercial insurers. Risk management--the activities required to minimise financial loss for hospitals and the doctors who work in them--is disorganised or absent in most hospitals. Hospital managers lack incentives for risk management because the costs of litigation do not come out of their budgets. The five mainstays of effective risk management are credentialling of medical staff, incident monitoring and tracking, complaints monitoring and tracking, infection control, and documentation in the medical record. The implementation of risk management activities in hospitals is the immediate responsibility of hospital management, not doctors.

Mesh:

Year:  2000        PMID: 10738478

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  3 in total

1.  The value of personal professional monitoring performance data and open disclosure policies in anaesthetic practice: a case report.

Authors:  S Bolsin; R Solly; A Patrick
Journal:  Qual Saf Health Care       Date:  2003-08

2.  Medical school attended as a predictor of medical malpractice claims.

Authors:  T M Waters; F V Lefevre; P P Budetti
Journal:  Qual Saf Health Care       Date:  2003-10

3.  Patients do not always complain when they are dissatisfied: implications for service quality and patient safety.

Authors:  Matylda Howard; Mary Louise Fleming; Elizabeth Parker
Journal:  J Patient Saf       Date:  2013-12       Impact factor: 2.844

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.